Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016

Medicine & Life Sciences

• United States Food and Drug Administration 100%
• Costs and Cost Analysis 62%
• Duration of Therapy 17%
• Therapeutics 16%
• Orphan Drug Production 13%
• Pharmaceutical Research 12%
• Placebos 12%
• Annual Reports 12%
• Equivalence Trials 12%
• Clinical Trials 11%
• Peer Review 11%
• Pharmaceutical Preparations 11%
• Drug Evaluation 11%
• Benchmarking 9%
• Control Groups 9%
• Industry 8%
• Evaluation Studies 8%
• Organizations 7%
• Publications 7%
• Health Care Outcome Assessment 5%
• Biomarkers 5%
• Delivery of Health Care 5%
• Population 3%